BigHat unveils next-gen ADC designed with Lonza’s Synaffix as lead program

CAR-T Digest - August 2020

04 Nov 2024: BigHat unveils next-gen ADC designed with Lonza’s Synaffix as lead program

BigHat Biosciences has secured commercial licensing rights to Synaffix’s ADC technology to enhance its ADC pipeline
BigHat plans to use its AI-driven antibody design platform, Milliner, to develop ADC candidates using Synaffix’s technologies: GlycoConnect, HydraSpace, and toxSYN
The agreement includes access to ADC offerings from Lonza, which acquired Synaffix in June 2023, further expanding BigHat’s capabilities
The partnership is pivotal for BigHat’s next-generation ADC program, currently in the IND-enabling stage, aimed at addressing high unmet medical needs in cancer treatment